Holen Sie sich die Stockscreener-App
28.32
2.42%
0.67
Handel nachbörslich:
28.42
0.10
+0.35%
Schlusskurs vom Vortag:
$27.65
Offen:
$28.27
24-Stunden-Volumen:
375.38K
Relative Volume:
1.36
Marktkapitalisierung:
$1.26B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-13.97%
1M Leistung:
+4.66%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$27.33
$29.19
1-Wochen-Bereich:
$27.33
$32.92
52-Wochen-Spanne:
$24.15
$33.32
Avalyn Pharma Inc Stock (AVLN) Company Profile
Firmenname
Avalyn Pharma Inc
Sektor
Branche
Telefon
(206) 707-0340
Adresse
105 W FIRST ST., BOSTON
Compare AVLN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
28.32 | 1.23B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalyn Pharma Inc Aktie (AVLN) Neueste Nachrichten
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Index - marketscreener.com
Avalyn Pharma Inc Actuals & Estimates (NASDAQ:AVLN) - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Value Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2000 Growth Benchmark - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 3000E Growth Benchmark - marketscreener.com
AVLN Forecast — Price Target — Prediction for 2027 - TradingView
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell Small Cap Completeness Index - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to Russell 2500 Value Benchmark - marketscreener.com
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Pharma (AVLN) Stock Chart and Price History 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs - BioPharma Dive
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Avalyn Pharma (AVLN) Earnings Date and Reports 2026 - MarketBeat
Avalyn Pharma (AVLN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Why is Avalyn Pharma stock surging today? By Investing.com - Investing.com UK
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone By Investing.com - Investing.com Canada
Avalyn Pharma stock rises on Phase 2b trial enrollment milestone - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial - Investing.com
Avalyn Pharma completes enrollment in pulmonary fibrosis trial By Investing.com - Investing.com Australia
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis - The Manila Times
Avalyn Pharma Ord Shs (Proposed) (AVLN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead - inkl
Morgan Stanley Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Avalyn Pharma Inc. 2026 Q1 Financial Report and Material Risks Overview - Minichart
Avalyn Pharma 1Q Loss $26.9M >AVLN - Moomoo
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Inc. 1Q 2026: Net income $(26.9M), EPS $(21.83) — 10-Q Summary - TradingView
Avalyn: Q1 Earnings Snapshot - marketscreener.com
AVLN: Q1 2026 net loss widened to $26.9M; IPO proceeds extend cash runway into 2029, but more funding needed - TradingView
Avalyn Pharma (Nasdaq: AVLN) widens Q1 loss but extends cash runway into 2029 - Stock Titan
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves - Yahoo Finance
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
Avalyn Pharma Inc.: Target Price Consensus and Analysts Recommendations | AVLN | US05348Y1055 - marketscreener.com
Avalyn to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Avalyn, inhaled-therapy company for rare respiratory diseases, at Jefferies - Stock Titan
AVLN Initiated Coverage by Morgan Stanley -- Price Target Set at $53 - GuruFocus
AVLN Initiates Coverage by Guggenheim -- Price Target Announced at $80 - GuruFocus
Finanzdaten der Avalyn Pharma Inc-Aktie (AVLN)
Es liegen keine Finanzdaten für Avalyn Pharma Inc (AVLN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Avalyn Pharma Inc-Aktie (AVLN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Carroll Jill | Director |
May 01 '26 |
Buy |
18.00 |
277,778 |
5,000,004 |
2,186,562 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 01 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
2,186,562 |
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):